Oncovita, a biotechnology company developing cancer vaccines and prophylactic vaccines, has appointed Stéphane Altaba as chief executive officer. With over 25 years’ experience in pharmaceutical R&D as well as business development, Dr Altaba will drive Oncovita’s development of drug candidates as well as collaboration agreements and licensing. Dr Altaba held R&D and business development roles at Sanofi and subsequently held senior management positions at Nordic Pharma Spa in Italy, where he was general manager, and at biotechnology companies such as Genomic Vision, LX Repair and RivelaDX. Dr Altaba holds a PhD in biochemical engineering from the University of Lorraine, France and completed a post-doctoral fellowship in Japan. Oncovita is a spinoff of the Institut Pasteur in France and raised €8 million in funding in 2023.
Oncovita announced the appointment on 9 October 2024.
Copyright 2024 Evernow Publishing Ltd.